Brolucizumab: Evaluation of Compassionate Use of a Complex Anti-VEGF Therapy

Figures & data

Table 1 Study Population

Patient Demographics	N = 98 Patients (%)
Age at treatment (years)  Mean (median, range)	71.4 (73, 95–34)
Sex
Male	52 (53.1)
Female	46 (46.9)
Race
Caucasian	51 (52.0)
Hispanic	42 (42.9)
African American	3 (3.1)
Asian	2 (2.0)

Table 2 Treatment Indication Distribution

Treatment Indication	N = 110 Eyes
Macular Edema	101 (91.8)
Radiation Retinopathy (Melanoma)	43 (42.6)
Epiretinal Membrane	17 (16.8)
Diabetic Retinopathy	13 (12.9)
Atypical Choroidal Nevus	7 (6.9)
Central Retinal Vein Occlusion	5 (5.0)
Radiation Retinopathy (Lymphoma)	4 (4.0)
Central Serous Retinopathy	3 (3.0)
Von Hippel Lindau Disease	3 (3.0)
Bests Disease	1 (1.0)
Branch Retinal Vein Occlusion	1 (1.0)
Epiretinal Membrane (Vitreomacular Tension)	1 (1.0)
Polypoidal Choroidal Vasculopathy	1 (1.0)
Radiation Retinopathy (Neovascular Glaucoma)	1 (1.0)
Radiation Retinopathy (Retinoblastoma)	1 (1.0)
Subretinal Neovascular Membrane	9 (8.2)
Myopia	4 (44.4)
Central Serous Retinopathy	4 (44.4)
Atypical Choroidal Nevus	1 (11.1)

Table 3 Demographics: Major Treatment Indications

Patient Demographics	Radiation Retinopathy	Epiretinal Membrane	Diabetic Retinopathy
N = 98 Patients	N = 41 Patients	N = 15 Patients	N = 12 Patients
Age at treatment (years)
Mean (median, range)	69.05 (70, 47–87)	75.41 (73, 57–95)	72.62 (68, 49–92)
Sex
Male	21 (51.2)	8 (53.3)	7 (58.3)
Female	20 (48.8)	7 (46.7)	5 (41.7)
Race
Caucasian	27 (65.9)	9 (60.0)	3 (25.0)
Hispanic	12 (29.3)	4 (26.7)	8 (66.7)
African American	1 (2.4)	2 (13.3)	1 (8.3)
Asian	1 (2.4)	0 (0.0)	0 (0.0)

Table 4 LOGMAR Visual Acuity for Total Population (Snellen VA Equivalent)

Brolucizumab Treatment	Mean	Median	Max	Min
Pre	0.89 (20/154)	0.65 (20/89)	2.9 (20/15,887)	0.097 (20/25)
Post	0.70 (20/100.5)	0.48 (20/60)	2.9 (20/15,887)	0 (20/20)

Note: N = 110 eyes.

Table 5 LOGMAR Visual Acuity by Major Treatment Indication (Snellen VA Equivalent)

Treatment Indication	Brolucizumab Treatment	Mean	Median	Max	Min
Radiation Retinopathy n = 43 Eyes	Pre	1.15 (20/284)	1 (20/200)	2.9 (20/15,887)	0.097 (20/25)
	Post	0.90 (20/159)	0.875 (20/150)	2.9 (20/15,887)	0.097 (20/25)
Epiretinal Membrane n = 17 Eyes	Pre	0.60 (20/79)	0.477 (20/60)	1.097 (20/250)	0.097 (20/25)
	Post	0.51 (20/65)	0.398 (20/50)	1 (20/200)	0.097 (20/25)
Diabetic Retinopathy n = 13 Eyes	Pre	0.88 (20/151)	0.602 (20/80)	2.301 (1/200)	0.176 (20/30)
	Post	0.72 (20/106)	0.544 (20/70)	1.824 (3/200)	0.097 (20/25)

Table 6 OCT CST of Total Population

Brolucizumab Treatment	Mean	Median	Min	Max
Pre	412.2	398.0	234.0	701.0
Post	340.7	324.5	209.0	599.0

Note: N = 110 eyes, measurement in microns.

Table 7 OCT CST of Major Treatment Indications (Microns)

Treatment Indication	Brolucizumab Treatment	Mean	Median	Max	Min
Radiation Retinopathy N = 43 Eyes	Pre	453.7	412.0	695.0	265.0
	Post	362.6	334.0	599.0	209.0
Epiretinal Membrane N = 17 Eyes	Pre	371.8	365.0	544.0	234.0
	Post	309.9	296.0	401.0	226.0
Diabetic Retinopathy N = 13 Eyes	Pre	418.3	454.0	541.0	279.0
	Post	353.4	349.0	498.0	231.0

Figure 1 Macular SD-OCT of 3 patients with macular edema secondary to radiation retinopathy (A), epiretinal membrane with myopic degeneration (B), and diabetic retinopathy (C). OCT B-scans before bevacizumab injection (ABC) and 6 weeks after bevacizumab injections (D–F) show no significant improvement. However, OCT comparison scans 6 weeks after brolucizumab injections show a marked improvement in macular anatomy (G–I).